Autologous genetically modified ADP-A2M4CD8 cells

GENETIC2 trials

Sponsors

Adaptimmune, USWM CT, LLC

Conditions

Esophageal CancerEsophagogastric Junction CancerOvarian Cancer

Phase 2

ADP-A2M4CD8 in HLA-A2+ Subjects With MAGE-A4 Positive Esophageal or Esophagogastric Junction Cancers (SURPASS-2)

TerminatedNCT04752358

AdaptimmuneEsophageal Cancer, Esophagogastric Junction Cancer

Start: 2021-09-15End: 2023-12-15Updated: 2024-09-04

ADP-A2M4CD8 Monotherapy and in Combination With Nivolumab in HLA-A2+ Subjects With MAGE-A4 Positive Ovarian Cancer (SURPASS-3)

Active, not recruitingNCT05601752

USWM CT, LLCOvarian Cancer

Start: 2023-06-26End: 2026-08-12Target: 66Updated: 2026-08-12

Related Papers

#24 A phase 2 study (GOG-3084) OF ADP-A2M4CD8 TCR T-cell therapy, alone or in combination with nivolumab, in patients with recurrent ovarian cancers

2023-09-011 citations

Safety and efficacy from the phase 1 SURPASS trial of ADP-A2M4CD8, a next-generation T-cell receptor T-cell therapy, in patients with advanced esophageal, esophagogastric junction, or gastric cancer.

Journal of Clinical Oncology2023-01-245 citations

Autologous T cell therapy for MAGE-A4<sup>+</sup> solid cancers in HLA-A*02<sup>+</sup> patients: a phase 1 trial.

2023-01-09145 citations

SURPASS-2 trial design: A phase 2, open-label study of ADP-A2M4CD8 SPEAR T cells in advanced esophageal or esophagogastric junction cancers.

Journal of Clinical Oncology2022-01-198 citations